Patents by Inventor Michael Lawrence Vazquez

Michael Lawrence Vazquez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof
    Patent number: 11981663
    Abstract: The invention provides novel benzamides of pyrazolyl-amino-pyrimidinyl derivatives of Formula (I) as selective and potent JAK inhibitors for treating various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Grant
    Filed: September 10, 2023
    Date of Patent: May 14, 2024
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20240124448
    Abstract: The invention provides a novel class of therapeutic agents that are safe and effective TYK2 inhibitors and pharmaceutical compositions of these compounds and methods of preparation and use thereof against various TYK2-mediated diseases and disorders.
    Type: Application
    Filed: September 25, 2023
    Publication date: April 18, 2024
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Gurmit Grewal, Xiaodong Li, Lin Su, Jingyu Wu
  • BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20240083882
    Abstract: Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Application
    Filed: October 6, 2023
    Publication date: March 14, 2024
    Inventors: Xiaodong Li, Michael Lawrence Vazquez, Zhaokui Wan
  • BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20240083881
    Abstract: The invention provides a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Application
    Filed: September 24, 2023
    Publication date: March 14, 2024
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20240025882
    Abstract: The invention provides novel benzamides of pyrazolyl-amino-pyrimidinyl derivatives of Formula (I) as selective and potent JAK inhibitors for treating various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Application
    Filed: September 10, 2023
    Publication date: January 25, 2024
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof
    Patent number: 11858933
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: January 2, 2024
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez
  • BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20230416235
    Abstract: The invention provides a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Application
    Filed: September 10, 2023
    Publication date: December 28, 2023
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof
    Patent number: 11851431
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Grant
    Filed: June 30, 2023
    Date of Patent: December 26, 2023
    Assignee: LYNK PHARMACEUTICALS CO. LTD.
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez
  • TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20230357247
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Application
    Filed: June 30, 2023
    Publication date: November 9, 2023
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez
  • TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20230339950
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Application
    Filed: June 30, 2023
    Publication date: October 26, 2023
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez
  • BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20230002362
    Abstract: The invention provides a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Application
    Filed: March 1, 2022
    Publication date: January 5, 2023
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220298144
    Abstract: The invention provides a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Application
    Filed: March 1, 2022
    Publication date: September 22, 2022
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez, Xiaodong Li
  • BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220259182
    Abstract: Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of their preparation and use thereof.
    Type: Application
    Filed: April 8, 2020
    Publication date: August 18, 2022
    Inventors: Xiaodong Li, Michael Lawrence Vazquez, Zhaokui Wan
  • TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220009927
    Abstract: The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).
    Type: Application
    Filed: November 1, 2019
    Publication date: January 13, 2022
    Inventors: Zhaokui Wan, Michael Lawrence Vazquez